Annexon, Inc.
A clinical-stage biopharmaceutical company developing therapies that target the complement system, the part of the immune system that helps clear damaged cells and defend against infection. Its lead programs focus on treating autoimmune and inflammatory diseases of the nervous system and eye. The company was founded in 2011 and is headquartered in Brisbane, California.
Bought 613.5K
Granted 30.6K · Sold 5.6K
Sold 4.3K
Sold 5.9K
Sold 5.6K
Sold 5.8K
Bought 24.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Satter Muneer ADirector · 1 transaction | — | 28.98M | — | 613.5K | — |
| Yednock TedEVP & CHIEF INNOVATION OFFICER · 2 transactions | +15.7% | 184.8K | 30.6K | — | 5.6K |
| Overdorf MichaelEVP & CHIEF BUSINESS OFFICER · 1 transaction | -2.3% | 182.6K | — | — | 4.3K |
| Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER · 1 transaction | -3.2% | 180.1K | — | — | 5.9K |
| Lew JenniferEVP & CHIEF FINANCIAL OFFICER · 1 transaction | -3.2% | 170.7K | — | — | 5.6K |
| Dananberg JamieCHIEF MEDICAL OFFICER · 1 transaction | -4.5% | 123.6K | — | — | 5.8K |
| Carson William H.Director · 3 transactions | +44.1% | 78.4K | — | 24.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +610.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.